The use, tolerability and ef®cacy of the non-steroidal anti-androgen nilutamide (Anandron 1 ) in daily clinical practice was investigated in this 5-y project. In total 725 patients were recruited from 27 Dutch centres. The investigated population was very heterogeneous and different therapeutic options were reported. We may conclude that in general good results have been obtained, especially in ®rst line combination therapy combined with luteinising hormone releasing hormone (LHRH) agonists. Patients with a good performance status at inclusion seem to bene®t more from nilutamide combination therapy. Prostate Cancer and Prostatic Diseases (2001) 4, 112±117.
Introduction
Prostate cancer is one of the most frequently diagnosed tumours in elderly men. 1 In spite of improved methods of screening an important number of patients are still diagnosed in an advanced cancer stage, frequently associated with boney or soft tissue metastases. Suppression of androgens has been the mainstay in the treatment of metastatic prostate cancer for nearly 60 y. 2 Suppression of androgens has been achieved by surgical castration (orchiectomy), estrogens, and more recently by chemical castration by the administration of luteinising hormone releasing hormone (LHRH) agonists. 3 Androgens of adrenal origin, may play a signi®cant role in disease progression. In 1945 Huggins and Scott had already reported a secondary response to surgical adrenalectomy in patients who had relapsed following orchidectomy. 4 The effects of androgens of adrenal origin can be suppressed by using anti-androgens. This is the concept of maximal androgen blockade (MAB). Anti-androgens can also be used to suppress the clinical consequences of¯a re-up; the initial rise in androgen levels caused by chemical castration.
Since 1990 the anti-androgen nilutamide (Anandron 1 ) has been registered and marketed in The Netherlands for advanced prostate cancer patients. Nilutamide is a nonsteroidal anti-androgen that binds speci®cally to the androgen receptor and is available in 50 and 150 mg tablets for once daily oral administration. 5 Initially nilutamide was registered for the prevention of¯are-up in the ®rst month after the start of an LHRH-agonist treatment, from 1996 it has been used for long-term use in combination with surgical or chemical castration.
Drug development does not stop with registration. It is the responsibility of practising clinicians and drug companies (the pharmaceutical industry) to continue to monitor the bene®ts and problems associated with the use of the drug once it is prescribed outside the strict criteria of clinical trials. In 1991, the Dutch Health Council introduced Post Marketing Surveillance (PMS) to the monitoring of all therapeutic effects, bene®cial or otherwise, resulting from commercial use of a drug. 6 PMS is part of the drug development assessment upon which rational, effective and safe prescribing should be based. The major criteria for a well-performed PMS include a non-interventional design to prevent selection bias, use of a representative patient population and a relatively high number of patients. 7 ± 9 This project was initiated in 1991 in The Netherlands, just after Dutch approval of nilutamide and was set up according to international guidelines for PMS. The goals of this project were to assess the use of nilutamide and to collect more safety and ef®cacy data from daily clinical practice of Dutch urologists.
Methods

Patients
In total 27 centers have participated in this project. Prostate cancer patients who had been prescribed nilutamide by their urologist were included. Upon receiving detailed information from the physician, patients were asked to give oral consent to store their data anonymously in a database, con®dentiality was strictly maintained throughout the project.
According to the company's core labelling, treatment with nilutamide should start with an initial treatment of 300 mg/day for 4 weeks, followed by a maintenance treatment of 150 mg/day from the 5th week onwards.
The observation period of the project was from the start of nilutamide treatment until discontinuation of nilutamide or until the cut-off date as decided by the sponsor. Visits of patients to the urologist took place according to the routine daily practice. The design and the performance of the project did not interfere with that routine practice. Only the urologist, who was treating the patient, could decide what the most appropriate investigations for his patient and treatment at any given time was.
Data handling and statistical procedures
All available data had to be compiled via patient report forms. Per patient visit a booklet had to be ®lled in including the data summarised in Table 1 . At the sponsor the completed forms were checked for inconsistencies. In case of any queries the investigator was asked for clari®cation by mail or via a personal visit.
All data received by the sponsor have been included in the evaluation.
For data handling and analysis purposes so-called reference dates were used instead of visit numbers, ie for all observations the time was expressed as the number of months after the start of treatment.
The statistical analysis was descriptive. The median survival times and progression-free intervals were computed according to Kaplan ± Meier's method. The progression free interval curves for the different strata were compared according to the Gehan ± Wilcoxon rank statistics.
In addition an explorative analysis was performed on the progression free interval data. The Cox proportionalhazards regression model was used to ®nd with a backward regression procedure the most signi®cant prognostic factors. Variables were progressively eliminated on the basis of the maximum partial-likelihood estimate (MLE) statistics, keeping those variables in the model whose MLE statistics satis®ed the criterion of a two-sided Pvalue less than 0.05.
Plots of the Score Ð and Schoenfeld residuals were used to assess the proportional hazard model assumptions.
Results
Patient recruitment
Recruitment of patients started in autumn 1991. However, some investigators ®lled in patient record forms retrospectively, the ®rst patient was included in July 1990. The last patient entered the project in April 1996.
The cut-off date of the project was November 1996. The last visit registered was March 1997.
Included in this ®nal analysis were all those patients with an initial visit case report form ®lled in. This yields a total of 725 evaluable patients, recruited from 27 different centers.
Demographic characteristics
The mean age of the patients was 74 y, ranging from 40 to 95 y. Almost all patients were Caucasian (99%).
One hundred and one (101 14%) patients had received hoped for' curative treatment, in most cases external beam radiotherapy. One third of the patients (n 234) had previously received hormonal therapy. One hundred ®fty-one had undergone orchiectomy, 67 patients had been treated with LHRH-agonists and 76 patients had already received other anti-androgens before inclusion.
Most of the patients were in good (63%) or average (31%) general condition. For 75% of the patients no metastatic related pain was reported. Severe metastatic pain was reported by only 4% of the patients. Three hundred and eighty-nine patients complained of mild to severe urinary obstructive symptoms.
Almost half of the patients (49%) had an Eastern Cooperative Oncology Group (ECOG) performance status equal to 0 at the start of nilutamide treatment.
A performance status of 1 (restricted in physically strenuous activity but ambulatory and able to carry out light work) was recorded in 31% of the cases. In only 7% of the patients was a performance status of 3 ± 4 reported at the time of inclusion in the project. The majority (64%) of the patients had a T3 or T4 tumour at baseline, 18% of the patients had a T2 tumour.
Half of the patients (50%) had boney metastases and 20% had soft tissue metastases at the start of nilutamide treatment.
Concomitant illnesses and medication
Almost 60% of the patients (n 427) reported one or more concomitant relevant diseases other than prostate cancer, the majority of which (n 279) were of cardiovascular origin.
Dosage and duration of treatment
Most patients received as a ®rst prescription a daily dose of 150 mg nilutamide (58%), 39% patients received a daily dose of 300 mg. At the second visit a daily dose of 150 mg was prescribed for most patients and only for six patients a daily dose of 300 mg was prescribed. For almost a quarter of the patients no dosage prescription was recorded at the second visit.
The observation period of the patients varied from less than 2 weeks (41 patients) up to 63 months (1 patient). The median number of follow-up visits per patient was three, with a range of 1 ± 20 visits. The mean time between the ®rst and second visit was 126 days. This is a rough estimation, because not all investigators ®lled in a report form at each visit.
Patient populations Ð nilutamide subgroups
The use of nilutamide could be subdivided into six subgroups: (1) nilutamide long-term combined with a LHRH-agonist (290 patients); (2) combined with orchiectomy (109 patients); (3) as prevention of¯are-up during the ®rst weeks of administration of an LHRH-agonist (33 patients); (4) in monotherapy (80 patients); (5) after progression after an LHRH-agonist (26 patients); (6) after progression at least 3 months after orchiectomy (83 patients). One hundred and four patients did not fall in any of these categories (eg patients who received nilutamide as neo-adjuvant therapy).
Compliance
Compliance was measured by asking the question at follow-up visits:`Has the patient taken nilutamide regularly?' In almost all cases (95%) this question was answered with`yes' in the record forms.
In this project, 516 patients discontinued treatment. Progression (n 202) and adverse events (n 132) were the most frequently reported reasons for discontinuation. Sixty-nine patients died and for 42 patients the treatment course was stopped after its use to prevent¯are-up with LHRH monotherapy. The majority of patients in this group used nilutamide for 4 weeks only.
Ef®cacy
All patients (n 725) with at least one case record form completed were included in this ®nal analysis. For 30 patients (4%) only one visit was registered as they were lost to follow-up. This means that the results do not add up to a total of 100%.
Complete regression was seen in 41% of the patients during treatment, partial regression was seen in 33% of the patients.
The best response to treatment for speci®c treatment groups was evaluated as well. Complete or partial subjective regression was reported for 86% of the patients starting nilutamide in combination with an LHRH-agonist. Of the 109 patients receiving nilutamide in combination with orchiectomy 76% reported regression. Sixty-six percent of patients receiving nilutamide in monotherapy (n 80) reported regression at any time in the project. Patients already in progression, using nilutamide after orchiectomy or after treatment with an LHRH-agonist reported less frequent`regression' (60%) than patients using nilutamide in combination with orchiectomy or an LHRH-agonist.
The subjective response per treatment group has been evaluated. It appeared that the group of patients receiving nilutamide in combination with an LHRH-agonist showed the best subjective response of all groups. At month 6, 86% of these patients (n 293) reported subjective regression, at month 18 (n 142) 84% were still in subjective remission.
For the 519 patients with performance status data after at least 6 months of treatment this status was compared with the baseline performance status. The performance status remained the same for 49% of the patients, in 12% of the cases there had been deterioration and in 40% there was an improvement in performance status after at least 6 months of treatment.
The prostate speci®c antigen (PSA) value is considered to be a biochemical marker for the status of prostate cancer. PSA-values at baseline and changes during treatment were evaluated: overall, 548 patients (76%) had a better nadir-PSA value during treatment than their baseline measurement, 104 (14%) patients did not achieve a lower PSA-value during treatment than measured at baseline, for 73 (10%) no PSA-data at baseline or followup were available.
For the group receiving nilutamide in combination with orchiectomy or an LHRH-agonist, respectively 84% and 79% had a PSA nadir lower than 4 ng/ml. From the patients who received nilutamide after progression after orchiectomy only 38% of the patients had after 6 months of treatment a nadir-PSA value lower than 4 ng/ml.
The Spearman rank-correlation coef®cient between the nadir-PSA value during treatment and the best subjective response equals 0.6597, (n 481).
The Spearman rank-correlation coef®cient between the relative change in PSA-value during treatment (nadir_PSA-baseline_PSA)/baseline_PSA) equals 0.6195 (n 431).
From the 725 patients, 276 patients had shown progression or died of their disease. The other 449 patients were regarded as censored.
The median progression free survival time was 14 months with a 95% con®dence interval of [12 ± 15] months. A sub-analysis of the patient groups receiving nilutamide in combination with an LHRH-agonist or in combination with orchiectomy showed a median progression free interval of 17 months in both groups. In the group of patients with a good performance status combining nilutamide with an LHRH-agonist, the median time to progression was 19 months; patients with a bad performance (2 ± 4) had a median time to progression of 13 months.
The progression free interval curves were calculated for patients with different baseline performance status. The P-value of the Gehan ± Wilcoxon test was 0.0025 indicating a signi®cant difference in time to progression whatever the treatment group was.
To ®nd possible prognostic factors in the Cox proportional hazards regression method the data collected at baseline and described in literature were used. To avoid a large reduction of the data set in the ®nal backward Cox regression procedure because of different amounts of missing values for the different prognostic factors, a uni-variate regression analysis was initially performed for possible prognostic factors. In the backward regression modelling the signi®cant uni-variate prognostic factors were included in the initial model: treatment group, performance status, presence of boney metastases, PSA, alkaline phosphatase (alk.p.) and haemoglobin.
In the ®nal model the prognostic factors PSA group, alk.p. group and haemoglobin concentration at baseline appeared to be signi®cant in predicting the progression free interval.
Safety
In total, 341 out of 725 patients (44%) reported adverse events. The most frequently reported adverse events were in the digestive system category (nausea and vomiting for 83 patients (11%)) followed by the nervous system (especially hot¯ushes 74 patients (10%)) and eye disorders (total of light/dark adaptation and visual disturbances; 57 patients (8%)).
In total, 471 adverse events were reported of which 164 (35%) were highly probably related to nilutamide treatment and 32% were reported as severe. Particularly eye disorders and gynaecomastia were reported as highly probably related to nilutamide, these symptoms were registered as severe in, respectively 4% and 15% of these adverse event symptoms. Liver function disturbance was reported in 12 patients, dyspnea was reported in 11 patients.
One hundred and thirty-two patients (132 18% of all patients) discontinued treatment because of adverse events.
A list of the 10 most frequently reported adverse events is given in Table 2 . Adverse events were also reported per treatment group. In the monotherapy group fewer adverse events were reported, 25% of the monotherapy patients, compared to 44% in total group.
In total, 100 serious adverse events, de®ned as life threatening were reported. From these events, three cases: dizziness, interstitial pneumonitis and liver injury/hepatocellular jaundice had been assessed as possibly related to nilutamide by both the investigator and the sponsor. In addition three events: one abdominal pain, one abnormal liver function, one pulmonary embolism (resulting in death) had been assessed as possibly related to nilutamide therapy by the urologist, but not by the sponsor.
In total, 69 patients died during the project. For one patient, who died because of multiple lung emboli, the investigator reported a possible relation with nilutamide.
Discussion and conclusion
In this multicentre, open, prospective PMS project we have tried to gain insight into the population receiving nilutamide, the therapeutic options and doses used, compliance, safety and ef®cacy of nilutamide in the treatment of prostate cancer in the daily practice of urologists has been studied. The major criteria for a well performed PMS project were met, such as a non interventional design to prevent selection bias and a relatively high number of patients. 7, 8 As might be expected, a non-interventional design results in an enormous variation in the timing of control visits and the number of data collected. This can be seen in the range of time between visit 1 and 2 and the number of visits per patient. For this reason the ef®cacy results of this PMS project have to be interpreted with care.
At the start of this project in 1991, nilutamide was only registered in The Netherlands for the prevention of are in prostate cancer patients during the ®rst month of LHRH-agonist treatment. Apparently most of the urologists did not prescribe nilutamide according to the registered indication, but prescribed nilutamide as à long-term' combination therapy supported by publications showing ef®cacy of maximal androgen blockade. 10 ± 13 Since 1996 nilutamide was registered as maintenance therapy together with castration.
The majority of the patients included in the project were at a relatively good clinical status. The general condition was assessed as good in 63% of the patients, no metastatic pain was recorded in 75% of the patients, and a performance status of 0 or 1 was recorded in 81% of the patients. However, almost one third of the patients had already received palliative treatment, including other anti-androgens (10%) before enrolment in this project. Most probably this has in¯uenced the results obtained in this project.
An important issue in prostate cancer is the monitoring of the response to therapy. Here PSA appears to be the most useful marker. In addition, the decrease of serum PSA after hormonal treatment appears to be an important prognostic factor. 14 The Spearman rank-correlation coef®-cient between the nadir-PSA value during treatment and the best subjective response con®rmed the anticipated relationship (0.66 for n 481).
For the group receiving nilutamide in combination with orchiectomy or an LHRH-agonist, respectively 84% and 79% had a PSA nadir lower than 4 ng/ml. These results are comparable with the results reported in the literature that after the start about 75 ± 80% of the patients reach a PSA nadir below 4 ng/ml after 3 or 6 months. 13, 15 In the literature only a small amount of data are available on the use of nilutamide as monotherapy. 17 In this project 80 patients (11%) received nilutamide monotherapy as indicated by the urologist. We have to be very careful interpreting these data, but the results obtained seem to be worthwhile. Although patients on nilutamide monotherapy did not respond as well as those on maximal androgen blockade, still 62% of the patients reported partial or complete subjective remission at any time after inclusion. Less adverse events occurred in the monotherapy group.
It is clear in the group of patients already in progression, who received nilutamide as second-line after orchiectomy or after treatment with an LHRH-agonist, were more often progressive than patients using nilutamide as monotherapy or in combination with orchiectomy or LHRH-agonist. The time to progression also differed signi®cantly between the therapy groups (P-value of the Gehan ± Wilcoxon test equals 0.0001). For the patients using nilutamide in combination with orchiectomy or LHRH-agonist the median time to progression is calculated separately for patients with a baseline performance status of 0 or 1, and patients with a baseline performance status of 2, 3 or 4. For patients using nilutamide in combination with an LHRH-agonist, a very clear difference could be shown between patients with a good (0 ± 1) and bad (2 ± 4) performance status. The median time to progression was respectively 19 months and 13 months and these data are comparable with data from the literature. For men with newly diagnosed metastatic disease, the median time to progression is 12 ± 18 months. 18 Again, we have to take into account that we are looking at a very heterogeneous patient population. Patients who did not report progression were censored and more patients were lost to follow-up compared to phase II/III trials with stringent inclusion criteria and more intensive monitoring.
In the ®nal model of the explorative analysis, the prognostic factors: treatment group, PSA, alkaline phosphatase and haemoglobin concentration were signi®cant in predicting progression free interval. These factors have also been described in the literature. 16 Although good results were obtained in patients with a good performance status treated by maximal androgen blockade, performance status could not be shown as one of the prognostic factors in this model.
The frequency of adverse events (related and nonrelated to nilutamide) were similar or less than in other studies investigating anti-androgens. 11 The most frequently reported adverse events were nausea and vomiting in 83 patients (11%) followed by hot¯ushes in 74 patients (10%) and eye disorders (total of light/dark adaptation and visual disturbances; 57 patients (8%)). Liver function disturbances and respiratory complaints have been reported as well but less than in other clinical studies. Although this is a positive result, we have to take into account that the data were only monitored`in-house' at the sponsor, no source data veri®cation was done, so this may have in¯uenced the results.
In summary we can say that PMS in prostate cancer patients is feasible. Although results have to be interpreted with care, interesting data can be collected. By more intensive monitoring and source data veri®cation, the quality of the data could be improved.
Good results have been obtained for the use of nilutamide in ®rst line combination therapy. Patients with a good performance status at inclusion seem to bene®t more from nilutamide combination therapy; their time to progression was delayed. Toxicity appeared to be comparable with or less than that already known from other studies.
The results from patients receiving anti-androgen monotherapy look promising but need to be further investigated, in prospective randomised trials.
